Capstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest Down 31.1% in February

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the recipient of a significant decrease in short interest in the month of February. As of February 27th, there was short interest totaling 103,151 shares, a decrease of 31.1% from the February 12th total of 149,731 shares. Based on an average daily trading volume, of 95,052 shares, the short-interest ratio is presently 1.1 days. Approximately 2.8% of the company’s stock are short sold. Approximately 2.8% of the company’s stock are short sold. Based on an average daily trading volume, of 95,052 shares, the short-interest ratio is presently 1.1 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Capstone Therapeutics in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Capstone Therapeutics Stock Down 0.1%

Capstone Therapeutics stock opened at $0.64 on Monday. The stock has a market cap of $5.79 million, a PE ratio of -0.67 and a beta of -1.23. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.95 and a quick ratio of 0.35. The stock’s fifty day moving average is $0.63 and its two-hundred day moving average is $0.89. Capstone Therapeutics has a 1-year low of $0.49 and a 1-year high of $4.18.

Institutional Trading of Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC acquired a new position in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned about 1.51% of Capstone Therapeutics at the end of the most recent quarter. 2.55% of the stock is owned by institutional investors and hedge funds.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.